A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)
Study description
M13-594 A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE- 3)
Pathology
Hepatitis C Virus HCV
Study type
Clinical trial
Status
Terminated
Study start date
2015
Study completion date
2017
Funder Type
Industry funded study
Investigator
Dr. med. Lorenzo MAGENTA
Recruitment
Completed